Clinical Trial Update: A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, and blood levels of GSK598809 in individuals with substance use disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Substance Use Disorder

Drugs mentioned

• GSK598809 (GSK598809)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Substance Dependence | Phase 1 | Status: COMPLETED